Qiagen, NeoGenomics to accelerate diagnostics for cancer meds

Qiagen (QGEN) and (NEO) announced a master service agreement to accelerate the availability of companion diagnostics that enable precision medicine for cancer patients. The partnership between Qiagen and NeoGenomics, a provider of cancer-focused genetic testing services, will ensure day-one patient access to FDA-approved molecular tests paired with newly approved drugs for cancer. Building on the FDA’s modernized regulatory approach to advanced diagnostics, especially next-generation sequencing, or NGS, tests, the collaboration with NeoGenomics will allow Qiagen and pharmaceutical partners to streamline the development and launch of targeted drugs and companion diagnostics to guide treatment decisions. The partnership offers pathways leading to introduction of FDA-approved companion diagnostics simultaneously with launch of new therapies. Qiagen and NeoGenomics will discuss their efforts to expedite access for precision medicine solutions at the American Society of Hematology, or ASH.
https://thefly.com/landingPageNews.php?id=2830709